Christopher Sayed, MD
Enriched profileProfessor, Department of Dermatology · University of North Carolina at Chapel Hill School of Medicine
Christopher Sayed is Professor, Department of Dermatology at University of North Carolina at Chapel Hill School of Medicine. OpenAlex indexes 171 publications with 2,735 citations (h-index 21); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Christopher Sayed, MD, is Professor, Department of Dermatology at University of North Carolina at Chapel Hill School of Medicine. The public record shows 171 publications with 2,735 citations (h-index 21), centered on Acne / Hidradenitis. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 14 companies, 2 NIH-funded awards (2020–2026).
- Most recent indexed publication: 2026 · The patient
- Top research focus: Acne / Hidradenitis
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Anifrolumab for Hidradenitis Suppurativa
Sponsor: University of North Carolina, Chapel Hill
- Wet-to-dry vs Petrolatum & Non-stick Dressings After Hidradenitis Suppurativa Surgery
Sponsor: University of North Carolina, Chapel Hill
- A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.
Sponsor: University of North Carolina, Chapel Hill
Industry payments
Updated 14 Oct 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202563 payments$111,977openpaymentsdata.cms.gov ↗
- UCB, Inc.Program year202510 payments$17,596openpaymentsdata.cms.gov ↗
- UCB SAProgram year20255 payments$13,355openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.1%TNF inhibitor16.6%Humira(Cf) Pen55%Remicade30%Inflectra15%Part D<11 patientsInterleukin-17A Antagonist10.4%Cosentyx Unoready Pen89%Taltz Autoinjector11%Part D<11 patients+ 5 more classes in this area
Anti-infectives
32.1%Lincosamide Antibacterial5.6%Clindamycin Hcl70%Clindamycin Phosphate30%Part D<11 patientsTetracycline-class Drug5.2%Doxycycline Hyclate100%Part D≥11 patients+ 6 more classes in this area
Dermatology
13.2%Corticosteroid13.2%Triamcinolone acetonide61%Triamcinolone Acetonide40%Part D + Part B≥31 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Determining the Genetic Basis of Hidradenitis Suppurativa
Univ of North Carolina Chapel Hill
FY2026$423,553R01AR083790 - Determining the Genetic Basis of Hidradenitis Suppurativa
Univ of North Carolina Chapel Hill
FY2025$395,810R01AR083790 - Determining the Genetic Basis of Hidradenitis Suppurativa
Univ of North Carolina Chapel Hill
FY2024$459,879R01AR083790
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The role of surgery in hidradenitis suppurativa: Expert-based holistic approaches.
Clinical and experimental dermatology
Article2026 - Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial.
The British journal of dermatology
Clinical Trial2026 - Genomic loci and molecular genetic mechanisms for hidradenitis suppurativa.
The British journal of dermatology
Meta-analysis2025 - Safety and efficacy of biologics in patients with Down syndrome and hidradenitis suppurativa: a retrospective cohort study.
Clinical and experimental dermatology
Article2025
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/christoph-sayed-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Apple Podcasts
podcasts.apple.com/us/podcast/derms-on-drugs/id1793832955
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - Other
hs-foundation.org/christopher-sayed-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hs-foundation.org ↗ - Other
webmd.com/podcasts/20251030/when-your-hs-treatments-stop-working-finding-new-paths-to-relief
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →webmd.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
University of North Carolina at Chapel Hill
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - Internal Medicine Internship
University of North Carolina at Chapel Hill
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - Dermatology Residency
University of North Carolina at Chapel Hill
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - Board Certified
Dermatology (American Board of Dermatology)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Director
Hidradenitis Suppurativa Clinic, UNC Chapel Hill
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - Vice President
Hidradenitis Suppurativa Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hs-foundation.org ↗ - Site Principal Investigator
industry- and NIH-funded HS clinical trials (e.g., BE HEARD I/II bimekizumab studies)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unchealth.org ↗
Media & interviews
press, podcasts and appearances- "Bimekizumab and Unmet Needs of Patients with HS, with Christopher J. Sayed, MD"
video interview, HCPLive
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗ - "Advances in HS treatment with Chris Sayed, MD"
video interview, Dermatology Times
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermatologytimes.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermatologytimes.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mdedge.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bradley Gaynes, MD
University of North Carolina at Chapel Hill School of Medicine
Alan Hinderliter, MD
University of North Carolina at Chapel Hill School of Medicine
Amy Mottl, MD
University of North Carolina at Chapel Hill School of Medicine
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania